Heart Transplantation
📧 Sign up to get email alerts when something new happens for Heart Transplantation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-03Clinical Trial Update: Evaluation of the Added Clinical Value of Donor-derived Cell-free DNA for the Monitoring of Cardiac Allograft Rejection.
This trial evaluated whether donor-derived cell-free DNA provides added clinical value for monitoring cardiac allograft rejection after hear…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation [Phase 4]
A completed Phase 4 clinical trial studied the pharmacokinetics of Modigraf (Tacrolimus Granules) in children following solid organ transpla…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients [Phase 4]
A pediatric open-label Phase 4 follow-up trial of Modigraf (tacrolimus) in de novo transplant recipients evaluating safety and efficacy; the…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Don't Throw Your Heart Away: Medical Student Study 2 [NA]
A completed clinical trial conducted by Carnegie Mellon University, focused on heart transplant recipients, has posted its results.
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
A clinical trial evaluating advanced cardiac imaging for cardiac allograft vasculopathy in heart transplant recipients has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: Cardiac Rehabilitation for Inpatient Heart Transplant (HRN4HTx) [NA]
The Cardiac Rehabilitation for Inpatient Heart Transplant (HRN4HTx) trial, sponsored by Instituto Politécnico de Bragança, has completed.
-
FDA approval · 2024-08-13FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MYFORTIC (mycophenolic acid) from Novartis. The approval expands its use for preventing orga…
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Mycophenolic Acid submitted by Aurobindo Pharma Limited under an ANDA, approving changes to …
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (ONESOURCE SPECIALTY PHARMA LIMITED)
FDA approved a supplemental application for mycophenolate mofetil submitted by Onesource Specialty Pharma Limited. The action pertains to ch…
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s supplemental application for mycophenolic acid, granting approval of the generic product under ANDA214630.…
-
FDA approval · 2024-07-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited, enabling approval of a generic formulation u…
-
CLINICAL_TRIALS research · 2024-06-21Clinical Trial Update: Effect of Resistance Training in Patients on the Waiting List for Heart Transplant [NA]
Clinical trial evaluating the effects of resistance training in patients on the waiting list for a heart transplant; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Brazilian Clinical Registry of Heart Transplantation
This entry details a Brazilian clinical registry study on heart transplantation. The study is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Donors After Circulatory Death Heart Trial [NA]
TransMedics completed the Donors After Circulatory Death Heart Trial, with results posted in May 2024. The trial evaluated donor strategies …
-
FDA approval · 2024-05-01FDA Approved: MYHIBBIN — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved MYHIBBIN, a mycophenolate mofetil product from Azurity Pharmaceuticals, under an original application (NDA216482). This approva…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Brachial Right Ventricle - Endomyocardial Biopsy
This entry notes the completion of a clinical trial studying brachial right ventricle endomyocardial biopsy in heart transplant recipients.
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Remote Ischemic Preconditioning and Acute Kidney Injury in HTX [NA]
A completed clinical trial evaluating whether remote ischemic preconditioning can reduce acute kidney injury in heart transplant recipients.
-
FDA approval · 2024-02-27FDA Approved: MYCOPHENOLIC ACID — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for generic mycophenolic acid from Aurobindo Pharma Limited. It is indicated as part of an immunosuppr…
-
FDA approval · 2024-02-07FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic version of mycophenolate mofetil from Hikma Pharmaceuticals USA, enabling continue…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score [Phase 3]
A Phase 3 clinical trial comparing tacrolimus with everolimus versus tacrolimus with mycophenolate mofetil in pediatric heart transplant rec…
-
FDA approval · 2023-09-14FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2023-09-14FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for PROGRAF (tacrolimus) from Astellas, updating the labeling for its use as an immunosuppressant to…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation [Phase 2]
Phase 2 clinical trial assessing the diagnostic validity of [18F]FSPG PET for detecting acute rejection after heart or liver transplantation…
-
FDA approval · 2023-05-08FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for mycophenolate mofetil from Ascend Laboratories, LLC under ANDA203005.
-
FDA approval · 2023-05-01FDA Approved: TACROLIMUS — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for tacrolimus by Sandoz Inc., resulting in a supplemental approval for the generic product. Thi…